Glaucoma Medical Therapy : Principles and Management: Principles and ManagementPeter A. Netland Siegal Professor of Opthalmology and Director of Glaucoma University of Tennessee Health Science Center Oxford University Press, USA, 2007 M11 16 - 312 páginas Glaucoma medical therapy has evolved with the advent of each new drug. This evolution has moved quickly and generated new information that clinicians need to understand, synthesize, and implement about medications that have specific benefits and risks for their glaucoma patients. This book aims to provide clinicians with an accessible guide to the current art and science of using clinically available drugs for the medical therapy of glaucoma. The contributors have attempted to present evidence-based information, while providing perspective from their clinical experience. In order to reflect the extensive changes that have occurred since the publication of the first edition in 1999, new chapters have been added about fixed combination drugs and the medical treatment of pediatric patients, and existing chapters have been thoroughly revised and updated. Glaucoma Medical Therapy will be a valuable reference for ophthalmologists in both practice and training, as well as for other practitioners who have clinical contact with glaucoma patients. |
Contenido
1 Ocular Pharmacology | 3 |
2 Prostaglandin Analogs | 33 |
3 Beta Blockers | 55 |
4 Adrenergic Agents | 79 |
5 Cholinergic Drugs | 103 |
6 Carbonic Anhydrase Inhibitors | 123 |
7 FixedCombination Drugs | 139 |
8 Osmotic Drugs | 151 |
11 Adjunctive Medical Therapy | 201 |
12 Special Therapeutic Situations | 215 |
13 Pregnancy and Pediatric Patients | 233 |
14 Compliance with Ocular Medication | 243 |
15 From Medical to Surgical Therapy | 259 |
SelfStudy Examination | 265 |
SelfStudy Examination Answer Sheet | 266 |
281 | |
Otras ediciones - Ver todas
Glaucoma Medical Therapy: Principles and Management Peter A. Netland Sin vista previa disponible - 2007 |
Términos y frases comunes
acetazolamide administration adrenergic agents agonists angle-closure glaucoma apraclonidine aqueous humor Arch Ophthalmol argon laser trabeculoplasty beta blockers betaxolol bimatoprost brimonidine brinzolamide CAIs carbonic anhydrase inhibitors cholinergic chronic ciliary muscle clinical trials clonidine compared compliance concentration corneal decrease dipivefrin disease dorzolamide dose drug delivery echothiophate efficacy elevated IOP epinephrine eye drops fixed combination glaucoma medications glaucoma or ocular glaucoma patients glaucoma therapy glycerol hypotensive increased initial intraocular pressure intravenous Invest Ophthalmol IOP elevation IOP reduction iridotomy iris latanoprost liposomes long-term lower IOP mannitol medical therapy miotics OBBs ocular hypertension ophthalmic drugs Ophthalmol Vis Sci Ophthalmology optic nerve oral osmotic drugs outflow facility PG analogs pigment pilocarpine primary open-angle glaucoma prostaglandin randomized receptors reduced IOP reduction in IOP regimen retinal risk side effects solution surgery surgical Surv Ophthalmol systemic target IOP therapeutic timolol timolol 0.5 timolol maleate topical trabecular meshwork trabeculectomy travoprost treated treatment twice daily uveoscleral visual field
Referencias a este libro
Maintaining the Target Intraocular Pressure: African American Glaucoma ... Sade Kosoko-Lasaki,Mildred M. G. Olivier,Edward Nathaniel Burney Sin vista previa disponible - 2005 |